These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18323849)

  • 1. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction.
    Wikberg JE; Mutulis F
    Nat Rev Drug Discov; 2008 Apr; 7(4):307-23. PubMed ID: 18323849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
    Nargund RP; Strack AM; Fong TM
    J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of melanocortin receptor small molecule ligands.
    Todorovic A; Haskell-Luevano C
    Peptides; 2005 Oct; 26(10):2026-36. PubMed ID: 16051395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system.
    Adan RA
    Trends Pharmacol Sci; 2006 Apr; 27(4):183-6. PubMed ID: 16500715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing drugs for the treatment of female sexual dysfunction.
    Brown AD; Blagg J; Reynolds DS
    Drug Discov Today; 2007 Sep; 12(17-18):757-66. PubMed ID: 17826689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ligands for melanocortin receptors.
    Kaelin CB; Candille SI; Yu B; Jackson P; Thompson DA; Nix MA; Binkley J; Millhauser GL; Barsh GS
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S19-27. PubMed ID: 19136986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Melanocortin system].
    Levitskaia NG; Kamenskiĭ AA
    Usp Fiziol Nauk; 2009; 40(1):44-65. PubMed ID: 19326848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene polymorphisms and their effects in the melanocortin system.
    Carroll L; Voisey J; van Daal A
    Peptides; 2005 Oct; 26(10):1871-85. PubMed ID: 15979205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feeding effects of melanocortin ligands--a historical perspective.
    Irani BG; Haskell-Luevano C
    Peptides; 2005 Oct; 26(10):1788-99. PubMed ID: 16046247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocortin-4 receptor agonists for the treatment of obesity.
    Boyce RS; Duhl DM
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1063-71. PubMed ID: 15535427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence for ancient role of ACTH peptides at melanocortin (MC) receptors; pharmacology of dogfish and lamprey peptides at dogfish MC receptors.
    Haitina T; Takahashi A; Holmén L; Enberg J; Schiöth HB
    Peptides; 2007 Apr; 28(4):798-805. PubMed ID: 17306418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased signaling at neural melanocortin receptors in regulation of energy homeostasis.
    Yang LK; Tao YX
    Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt A):2486-2495. PubMed ID: 28433713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.
    Ückert S; Bannowsky A; Albrecht K; Kuczyk MA
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1477-83. PubMed ID: 25096243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanocortin receptors as drug targets for disorders of energy balance.
    Adan RA; van Dijk G
    CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):251-61. PubMed ID: 16787227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting melanocortin receptors as a novel strategy to control inflammation.
    Catania A; Gatti S; Colombo G; Lipton JM
    Pharmacol Rev; 2004 Mar; 56(1):1-29. PubMed ID: 15001661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the central melanocortin system for the treatment of metabolic disorders.
    Sweeney P; Gimenez LE; Hernandez CC; Cone RD
    Nat Rev Endocrinol; 2023 Sep; 19(9):507-519. PubMed ID: 37365323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting melanocortin receptors as potential novel therapeutics.
    Getting SJ
    Pharmacol Ther; 2006 Jul; 111(1):1-15. PubMed ID: 16488018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of proline based melanocortin receptor ligands.
    Tian X; Field T; Mazur AW; Ebetino FH; Wos JA; Crossdoersen D; Pinney BB; Sheldon RJ
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2819-23. PubMed ID: 15911261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.
    Pfaus JG; Shadiack A; Van Soest T; Tse M; Molinoff P
    Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10201-4. PubMed ID: 15226502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.